EVREN ALICI

Professor Alici is a distinguished researcher at Karolinska Institutet. His research focuses on the fields of multiple myeloma and sarcoma, specifically on the use of NK cell-based immunotherapies in cancer. He leads many ongoing clinical phase I and II trials where NK cells are used to combat these diseases, and is an renowned expert in retro and lentiviral vector production for clinical use.

Professor Alici serves as co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies, and is Vice president of the Swedish Society of Gene and Cell Therapy.

He has served as an advisor to more than a dozen cell and gene therapy companies. He has over 50 peer-reviewed publications with a total of over 2000 citations, holds six patents all stemming from his research, and serves as editor of several scientific journals.